Brief: An2 Therapeutics Inc - License Enables Advancement Of An2-502998
18/10/2023 12:02
Oct 18 (Reuters) - AN2 Therapeutics Inc ANTX.O :
* AN2 THERAPEUTICS SIGNS LICENSE AGREEMENT WITH THE
UNIVERSITY OF
GEORGIA RESEARCH FOUNDATION TO DEVELOP NOVEL BORON-BASED THERAPY
FOR CHAGAS DISEASE
* AN2 THERAPEUTICS INC - LICENSE ENABLES ADVANCEMENT OF
AN2-502998
Source text for Eikon: ID:nBw2Z4gg8a
Further company coverage: ANTX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on AN2 Therapeutics
See all newsBrief: AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(C)(4)
Brief: An2 Therapeutics Announces Extension Of Funding For Tuberculosis Research Collaboration With Gsk
AN2 Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
AN2 Therapeutics Q2 net loss widens on higher R&D costs
AN2 Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview